[go: up one dir, main page]

WO2015153900A1 - Kits de préparation de sites d'administration d'un médicament - Google Patents

Kits de préparation de sites d'administration d'un médicament Download PDF

Info

Publication number
WO2015153900A1
WO2015153900A1 PCT/US2015/024118 US2015024118W WO2015153900A1 WO 2015153900 A1 WO2015153900 A1 WO 2015153900A1 US 2015024118 W US2015024118 W US 2015024118W WO 2015153900 A1 WO2015153900 A1 WO 2015153900A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
injector
formulation
kit
alignment ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/024118
Other languages
English (en)
Inventor
Andrew Michael Blumenfeld
Brooks M. Boyd
Jeffrey A. Schuster
John Turanin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zogenix Inc
Original Assignee
Zogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zogenix Inc filed Critical Zogenix Inc
Publication of WO2015153900A1 publication Critical patent/WO2015153900A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum

Definitions

  • the current invention is directed towards drug delivery systems and kits for
  • Self administration of injectable medications, or administration by a nonprofessional such as a family member has numerous advantages, including the ability to rapidly and/or regularly self dose medications for conditions such as pain, anaphylaxis, hyperglycemia, etc. without the need for visiting a doctor's office or access to a skilled care giver. Rapid self administration is facilitated by the use of a drug delivery system that is self contained including an on-board power source (e.g. an auto-injector), factory pre-filled, portable, small enough to be carried in a pocket book or glove compartment, single use, and disposable.
  • an on-board power source e.g. an auto-injector
  • factory pre-filled portable, small enough to be carried in a pocket book or glove compartment, single use, and disposable.
  • self administration problematic. These factors include pain, bleeding, bruising, swelling, cutting, erythema, infection, and/or other local effects at the delivery site, and can lead to fear and patient non-compliance or switching to other delivery methodologies that may not be as effective
  • Numerous drug delivery systems for self administration or home administration are available, including but not limited to needle and syringe, auto injectors, needle free injectors, pumps, bolus injectors, sprays, infusion systems, gene therapy systems, catheters, and transdermals including active and passive transdermals,
  • Injection of medications can have many advantages, including rapid onset, high bioavailability, avoidance of first pass metabolism, and low coefficient of variation. Needle free injection has numerous advantages over injection using a needle and syringe, including avoidance of needle stick injury, avoidance of needle phobia, and avoidance of the need for sharps disposal.
  • Needle free injectors while addressing some of the issues related to injection with a needle and syringe, have particular requirements to ensure that self administration is easy and comfortable for patients. Among these requirements is the fact that the delivery must occur with the nozzle in contact with (or in some instances such as intra-dermal delivery, at a fixed distance to) the desired injection site on the target organ or skin. Most needle free injectors should be activated with the device perpendicular to the skin or target organ at the desired injection site. Moving the injector during delivery can be problematic and in the worst cases lead to distortion of the injection path in the target organ. At times there can be pain associated with needle free injection. The experience of this pain may be worsened by the expectation on the part of the patient of little or no pain due to the lack of a needle.
  • An embodiment of the invention includes a dual function, injector device
  • a needle-free injector which is comprised of a first container holding a first formulation comprising a first pharmaceutically active drug in a liquid container, a piston for forcing the first drug from the container at a speed which penetrates skin, a channel leading from the first container to an exit opening, a second container holding a second formulation comprising a second pharmaceutically active drug, generally different from the first pharmaceutically active drug, and an applicator for applying this second drug topically to the surface of a target organ (often the skin) of a human patient
  • the first drug is typically any drug which has a systemic pharmacological effect on a human patient and the second drug is a drug which has a local effect such as decreasing pain, bleeding, swelling, erythema, infection, and bruising
  • the formulation containing the second drug is formulated for topical application and as such is preferably viscous having a viscosity of lOcp or more, 20cp or more, lOOcp or more, 200cp or more wherein the formulation
  • One embodiment of the current invention comprises needle free injector which includes a removable orifice cap that closes the orifice and ensures that the injector contents are maintained in a stable, sterile container closure system.
  • the injector cannot be triggered prior to or during removal of the cap, which also functions as the container and topical applicator for locally active drugs such as vaso-constricting agents, absorption enhancing agents, anesthetic agents, adhesive agents, vacuum sealing agents, cleaning agents, depilatory agents, and/or anti-microbial agents.
  • the cap may include one or more local anesthetic agents and may include additional components to facilitate local absorption, such as an absorption enhancer, a needle, an abrasive, or an array of needles or microneedles.
  • the cap is removed, pressed and/or rubbed against the desired injection site, possibly in combination with squeezing of the cap, and the needle free injection is then applied to the prepared injection site after an optional pre-specified wait time.
  • the injector is a needle and syringe which is preferably prefilled, with a similar cap that covers the needle to prevent needle stick and possibly maintains the contents in a stable, sterile manner.
  • Related embodiments may comprise other drug delivery devices such as transdermal devices, pumps, bolus injectors, and catheters.
  • local drug delivery effects e.g. local injection effects, including but not limited to pain, bleeding, bruising, swelling, erythema, infection, and injection path distortion.
  • the container is factory prefilled with the topical drug(s), and is presented with an overwrap or removable cover that maintains the stability and/or sterility of the formulation.
  • the container comprises a rigid or semi-rigid cup containing a compliant material, such as a sponge.
  • the compliant material is contained in the cup in a partially compressed state by a removable and disposable cover or cap.
  • the compliant material is factory infused with the topical formulation.
  • the cover or cap is removed, the partially compressed compliant material expands, such that it extends beyond the opening in the cup.
  • the cup is then gripped, and the compliant material is pressed or rubbed against a target site on an organ, for example an injection site on skin.
  • the cup is semi-rigid, and the pressing or rubbing is combined with squeezing to maximally deliver the infused formulation. After a single delivery, the cup and compliant element are disposed of. [014] It is an object of the invention to prepare a surface for treating or preventing the occurrence of a condition by delivering, preferably injecting, an API.
  • the condition is a migraine or cluster headache
  • the API is a triptan.
  • vaso-constricting agent delivery site by the application of a vaso-constricting agent.
  • Preferred additional drugs of the inventions include but are not limited to topical anesthetic agents, including but not limited to benzocaine, lidocaine, tetracaine;
  • vasoconstricting agents including but not limited to epinephrine, an absorption enhancing agent including but not limited to hyaluronidase, and combinations thereof.
  • vasoconstricting agent in combination with a local anesthetic increases the duration of effect of the anesthetic by constricting the local blood vessels.
  • compounds including but not limited to additional drugs, adhesives, cleaning agents, antimicrobials, depilatory agents, vacuum sealing agents, and/or other compounds in a convenient package or kit that facilitates storage of the drugs with an injector or other drug delivery device.
  • kits or devices which includes a drug delivery device and additional, non-injected compounds including but not limited to additional drugs, adhesives, vacuum sealing agents, cleaning agents, antimicrobials, depilatory agents, absorption enhancing agents, and/or other compounds in a convenient package that facilitates delivery of the additional non-injected compounds.
  • the drug delivery system is supplied with a cap, such as a needle cap, catheter cover, transdermal device cover, or a needle free injector orifice cap, that also functions as the container for additional compounds, and is also the applicator for topical application of additional compounds.
  • a cap such as a needle cap, catheter cover, transdermal device cover, or a needle free injector orifice cap, that also functions as the container for additional compounds, and is also the applicator for topical application of additional compounds.
  • an on-board power source i.e. an auto-injector
  • factory pre-filled portable, small enough to be carried in a pocket, purse, or glove compartment, single use, and/or disposable.
  • a needled injector including but not limited to a needled injector, a needle free injector, a transdermal, a pump, a bolus injector, an infusion system, or a catheter does not move relative to the treatment site during treatment.
  • the organ is a patient' s skin.
  • a drug delivery device preferably an injector, more preferably a needle-free injector, with a component that pulls outward and stretches the surface of the target organ, facilitating efficient delivery
  • kits and/or a delivery device functions selected from a cap, a container for additional, non-injected and/or non-systemically delivered compounds, an applicator for additional, non-injected and/or non-systemically delivered compounds, a component that ensures that the drug delivery device is held at a desired orientation, doesn't move, and is at a pre-specified distance from a target organ or in contact with a target organ, and a component that pulls up and stretches the surface of a target organ, are included in a single part or assembly.
  • injector with an attached component that ensures that the injector is held at the desired orientation, doesn't move, and is in contact with the skin or at a pre-specified distance from the skin, during injection.
  • the area of contact of the alignment ring with the target organ may be of any shape.
  • the area of contact is cirucular, with an injection orifice or needle or arrays thereof substantially centered on the circle.
  • other shapes may be used, including but not limited to squares, pentagons, hexagons, etc.
  • the alignment ring may also comprise a plurality of extensions extending radially from the drug delivery device. Any number of extensions can be used, although it is preferred that there be more than two extensions to maintain the orientation of the device about any rotation axis. Preferably there are three or more extensions, more preferably 4 extensions.
  • the patient Preferably, the patient cannot tell if the injector is needled or needle free.
  • the needle or catheter of a drug delivery device does not allow the patient to see the orifice of a needle free injector, does not allow the patient to see the delivery site, and/or does not allow the patient to see the insertion of the needle, catheter, or the like.
  • the injector is a needle-free injector, and the component also ensures that the skin is in contact with an injection orifice.
  • the drug delivery device is a needle free injector with one or more injection orifices, that is triggered by pressing the orifice or orifices against the skin of a human or animal patient.
  • the drug delivery system is supplied as a kit with a separate alignment component or "alignment ring" that is adhered to the skin prior to delivery, contained in a package with an instruction for use and a label. Subsequently, the injector is inserted into the alignment component to a desired depth, and the formulation is delivered.
  • the alignment ring ensures that the injector is held at a predetermined angle to and at a predetermined distance from the target organ or skin, preferably perpendicularly, and additionally ensures that that the injector does not move relative to the skin surface during injection.
  • the orifice end of the injector is inserted into and through the alignment ring until the orifice is pressed against the target organ or skin, or (for example for an intra-dermal injection) held at a fixed distance from the target organ or skin.
  • the force of the orifice being pressed against the target organ or skin actuates the trigger.
  • the device being pressed against the spacer triggers the device.
  • combination with the length of the needle can set the depth of injection, for example for an injection chosen from an intra-dermal, sub-cutaneous, intra- venous, or intra-muscular injection.
  • the alignment ring can also have features that interact with mating features such as actuators on the injector.
  • the feature on the alignment ring and injector can enable the injector for triggering or delivery, trigger the injector in the embodiment where the injector is an auto-injector, insert a retractable needle, expose the orifice of a needle free injector, etc.
  • the alignment ring embodiment preferably comprises an adhesive that holds the alignment ring in the desired location on the skin or target organ.
  • the adhesive is pre-applied to the alignment ring.
  • the adhesive may be a two sided adhesive tape which is dye cut and factory applied to the alignment ring, with the outer adhesive layer covered, for example by a release liner.
  • the release liner may be removed, for example via an exposed tab, prior to adhering the alignment ring to the target injection site.
  • the release liner may be attached to the device packaging or to another component, and the act of removing the alignment ring from its packaging or another component removes the release liner.
  • the adhesive may be a high viscosity liquid adhesive that is factory applied to the alignment ring and covered by a protective sheet or cap.
  • the kit contains a separate applicator for an adhesive that is applied to the target injection site or to the alignment ring immediately prior to placement of the alignment ring.
  • the applicator is a cap for the drug delivery system, for example an orifice cap, needle or catheter cap, or a cover for a transdermal skin contact area.
  • adhesive is contained in a second formulation which optionally comprises one or more APIs for the reduction of local effects.
  • the alignment ring contains one or APIs for the reduction of local effects in the central region of the alignment ring into which the injector and optional needle is inserted.
  • the alignment ring is adhered to the desired delivery site for a wait time that is sufficient to allow the APIs to take effect, and then the drug delivery system is inserted and the first formulation is delivered.
  • the injector is supplied with an attached
  • the alignment ring that functions as a vacuum cup which surrounds one or more injection orifices or needles, and a vacuum source.
  • the vacuum source may be separate from the injector, and pneumatically attached to the injector, for example via flexible tubing.
  • the vacuum source is contained within the injector, and most preferably the vacuum source is actuated by the person giving the injection, for example via a lever, preferably via a thumb actuated lever.
  • the vacuum source is actuated by the act of pressing the injector against the desired delivery site.
  • the vacuum cup utilizes the vacuum to seal to the desired injection site, ensuring that the injector cannot move during the injection.
  • the vacuum cup act as an alignment ring and ensures that the injection occurs at a preferred angle to the skin at the desired injection site, preferably perpendicularly. This is accomplished both by the vacuum drawing the skin into the vacuum cup and against the orifice or orifices, and by the vacuum cup being large enough that the injector itself is held at the desired angle to the skin.
  • the triggering of the device is interlocked to the vacuum, ensuring that the device can only be triggered when the vacuum cup is in sealing contact with the skin. More preferably, the vacuum itself actuates the device trigger.
  • the injector is an auto-injector that is powered by a compressed gas that is contained within the injector, and the vacuum actuates a valve, preferably a spool valve, which releases the compressed gas, causing the auto-injector to deliver.
  • the delivery that facilitates the desired delivery kinetics and drug dynamics, such as oral, buccal, nasal, pulmonary, rectal, vaginal, transdermal, ocular, or parenteral, including intra-muscular, intra-dermal, sub-cutaneous, intra- arterial, or intravenous, or direct delivery to an organ, it is preferably not oral, more preferably nasal, pulmonary, buccal, or parenteral.
  • the delivery is intra-dermal injection, intra-muscular injection, or most preferably subcutaneous injection, and in the most preferred embodiment, the formulation is delivered by needle free injection via the sub-cutaneous route.
  • the invention is carried out utilizing a pre-filled, self
  • the invention is carried out using a needle free injector that is powered by a self contained compressed gas charge as described in U.S. Patent No. 5,891,086 (incorporated by reference in its entirety).
  • 5,891,086 describes a device for delivering formulations, including viscous formulations, by needle-free injection for SC, ID or IM, but not limited to these applications.
  • a latch within said housing which engages said impact member to prevent movement of the impact member toward the forward portion in response to said force exerted by said pressurized gas, and being mounted to be movable out of engagement with said impact member to a firing position, in which said latch permits such movement.
  • the current invention describes various formulations that can be delivered using a needle-free injector including the injector of 5,891,086. These formulations contain active ingredients, and may include various polymers, carriers, etc. [056] Additional preferred embodiments of the needle free injector can be found in WO 2012/096889 Al
  • Another preferred embodiment is the needle free injector with multi-use actuator as described in US patents 7,281,502, 7,351,220, and 7,814,871
  • An aspect of the invention is a desirable delivery time of high viscosity formulations.
  • Another aspect of the invention is acceptable pain associated with injection
  • Another aspect of the invention relates to alleviation of fear of needles
  • Another aspect of the invention relates to the elimination of the danger of needle stick injury and cross-contamination associated with injection of migraine formulations.
  • Another aspect of the invention relates to the simplification of preparation associated with injection of formulations, by supplying a pre-filled, single use disposable injector.
  • Another aspect of the invention relates to the drug release profile associated with injection of high viscosity depot formulation, especially surface eroding systems.
  • kits aspect of the invention may comprise a needle free injector which comprises a first container holding a first formulation and a second container holding a second formulation.
  • the first formulation is generally comprised of a pharmaceutically active drug which has systemic activity and the second formulation is generally comprised of a second pharmaceutically active drug different from the first drug which has a local topical effect.
  • the device may include a topical applicator configured to deliver the second formulation to the surface of an organ such as the patient' s skin and may also include a package which includes all of the components.
  • the containers are preloaded with a desired formulation and the entire device is disposable.
  • One embodiment of the invention is a dual function needle free injector device which is comprised of two different container which hold two different drug formulations wherein one formulation is for systemic delivery to treat a patient and the second formulation is for topical application.
  • the topical formulation may be an anesthetic alone or with other drugs which have other topical effects.
  • the device such as the needle free injector may be connected to an alignment ring which makes it possible for the patient to correctly align the drug delivery device such as the needle free injector with the patient's skin.
  • the alignment ring may include adhesive and may be positioned such that the needle-free injector will fire the drug formulation through the skin at an angle of approximately 90° + 10°.
  • FIG. 1 shows an embodiment of the injector of the current invention, with a cap/applicator attached.
  • Fig. 2a shows an embodiment of the cap/applicator of the current invention.
  • Fig. 2b shows a cross sectional view of the cap/applicator of Fig. 2a.
  • Fig. 2c shows the cap/applicator of Fig. 2a in use.
  • Fig. 3 shows one embodiment of the alignment ring of the current invention.
  • Fig. 4 shows one embodiment of the vacuum cup and vacuum source
  • Fig. 5a shows a cross section of the spool valve vacuum trigger of the
  • Fig. 5b shows the cross section of Fig. 5a after triggering.
  • Fig. 6a shows an embodiment of the topical applicator of the current
  • Fig. 6b shows the embodiment of Fig. 6b after removal of a cover.
  • FIG. 7 shows another embodiment of the vacuum cup and vacuum source
  • FIG. 8 shows another embodiment of the current injection, with a
  • deformable or moveable alignment ring that grips and raises the surface of the target organ at the desired injection site.
  • Figure 8b shows the embodiment of figure 8 after pressing against the
  • Active Pharmaceutical Ingredient API, active drug substance, medicament, or the like: A component of a pharmaceutical formulation that is pharmaceutically active and is delivered for a desired effect.
  • Actuator A mechanical device for moving or controlling a mechanism
  • actuators include a lever that a user uses to ready a drug delivery system for delivery, a lever that creates a vacuum, a lever and linkage designed to operate a deformable or movable alignment ring, or a button, lever, or the like that is used to trigger delivery from a drug delivery system.
  • An actuator may be actuated directly by a user, or may be actuated by relative movement of two components of a drug delivery system or kit, such as insertion of an injector into an alignment ring.
  • An actuator may actuate a component of a drug delivery device directly through a linkage or push rod or the like, or it may act indirectly, for example by generating a vacuum that acts on a vacuum cup and/or a trigger mechanism.
  • an actuator can refer to the mechanical portion of an auto-injector that comprises an energy store, an optional safety that must be set prior to delivery, a trigger for the device, and components that ensure the proper pressure profile during delivery.
  • Ambient Pressure The pressure of the atmosphere surrounding an injector during an injection. Ambient pressure can vary, for example with elevation and weather.
  • API Active Pharmaceutical Ingredient or drug
  • Applicator Topical Applicator, and the like: A component which serves as a delivery system, and preferably as a container closure system, for a formulation which is applied to the surface of an organ, preferably the skin.
  • the formulation may contain APIs, such as vasodilators, local anesthetics, and/or anti-microbials, and may also contain other ingredients, such as absorption enhancers, adhesives, vacuum sealing agents, depilatory agents, cleaning agents, and the like.
  • the topical applicator may be supplied as a standalone product, but is preferably supplied as part of a kit which includes a drug delivery system.
  • the topical applicator comprises a cap for a drug delivery system, for example an orifice cap, a needle or catheter cap, or a cover for the skin contact area of a transdermal system.
  • the applicator is preferably supplied with a cover or overwrap that maintains the stability and/or sterility of the contained formulation.
  • the applicator cover or overwrap may be removed by the user prior to use as a separate step.
  • the act of removing the applicator from a kit, a package, or another component such as a drug delivery system removes the cover.
  • the cover or overwrap comprises one or more polymers, including but not limited to include polyethylene, polyester, nylon, cyclic olefin copolymer, and polychlorotrifluoroethylene, and may comprise one or metals including aluminum.
  • the formulation is applied to a desired delivery site by rubbing or pressing the applicator on the desired site site, optionally while extruding the second formulation by or after squeezing the applicator container, manipulating an actuator such as a depressing a plunger, pressing a button, moving a switch or actuating a lever, etc. or a combination thereof
  • AUC Area under the curve, or the integral, of the plasma concentration of delivered drug over time.
  • Auto-Injector an injector for delivery a formulation containing an active pharmaceutical ingredient, wherein the energy for the delivery is supplied by the injector rather than being sourced by the patient or a care giver during delivery.
  • An Auto-Injector will have a trigger for releasing the energy and initiating drug delivery, and optionally will have a safety mechanism and/or a mechanism for setting the delivered dose.
  • the trigger can be, for example, a push button, but the auto-injector is preferably designed so that it cannot be triggered unless it is pressed against the desired injection site, for example by pressing it against the desired injection site or by ensuring a vacuum is present indicating that the device is sealed to the injection site.
  • Auto-injectors may be single use or multi use, and fixed dose or variable dose.
  • Preferred auto-injectors prefilled, compact, portable, fixed dose, single use disposable needle free injectors.
  • Other preferred embodiments include multiuse actuators with multi-dose drug reservoirs, or more preferably, with removable, single dose disposable drug reservoirs.
  • Preferred energy sources include pressurized gas or combustible materials, but may also include mechanical springs or chemical or electro-chemical sources such as batteries or pyrotechnic charges.
  • Bayonet Fitting a mechanism for removably attaching two components in a way similar to how a bayonet is attached to a rifle.
  • one of the components has a pin, and the other has a mating slot or groove which has a right angle bend. To separate the components, both are gripped, rotated relative to each other, and then pulled apart.
  • Bolus Injector a drug delivery device that delivers an infusion of a drug over a longer period than would be comfortable using a needle and syringe.
  • Bolus injectors are similar to pumps, but in general require shorter delivery times than pumps.
  • Bolus injectors generally have a needle or catheter, but may be needle free or transdermal.
  • Bolus injectors can deliver through a tube such as an infusion set, or may attach directly to the skin.
  • Preferably bolus injectors deliver over a time greater than 1 minute, greater than 5 minutes, greater than 10 minutes, or greater than 30 minutes.
  • bolus injector deliver over a time less than 5 hours, preferably less than 3 hours, more preferably less than 1 hour.
  • Cap a component that covers a component of a drug delivery system.
  • the covered component contains the route through which the API is delivered to the target organ.
  • the cap may cover the needle of a needled injector, a catheter, the skin contact surface of a transdermal, the microneedles of a microneedle array, or preferably one or more orifices of a needle free injector.
  • Caps preferably maintain sterility and stability of prefilled formulations, and minimize water vapor transmission rate. Caps minimize needle stick injury when used with needled injectors, and keep the orifices of needle free injectors free of dust and other contaminants that can impact jet formation.
  • the injector is an auto-injector with a trigger, and the trigger is interlocked to the cap to ensure that the cap is removed before delivery can be initiated.
  • the device has features that ensure that the removal of the cap cannot cause the device to trigger. This is especially important for needle free injectors that are triggered by pressing the orifice against the desired injection site.
  • the cap also comprises a container closure system and/or applicator for a second, non injected, topically applied formulation (see "Topical Applicator").
  • the second formulation is indicated to reduce local effects, including but not limited to bleeding, erythema, infection, bruising, pain, and/or swelling.
  • the second formulation contains APIs including but not limited to vaso-constricting agents, absorption enhancing agents, one or more local anesthetic agents, and mixtures thereof.
  • the cap also functions as an applicator for the second formulation, whereby the second formulation is applied to a desired injection site by rubbing the cap on the desired injection site, optionally while extruding the second formulation by squeezing the cap, manipulating an actuator such as a plunger or lever, etc.
  • the cap may also contain other, preferably liquid, compounds, including but not limited to adhesives and/or vacuum sealing media.
  • Catheter a tube that can be inserted into a body to perform a medical
  • Cluster headaches are extremely painful, piercing,
  • the unilateral property may shift from one side of the head to the other between events, or rarely may shift during a cluster headache event.
  • Other symptoms may include ptosis (drooping eyelid), conjunctival injection (red-eye), lacrimation (tearing), rhinorrhea (runny nose), restlessness and pacing, and, less commonly, facial blushing, swelling, sweating, and/or aversion to bright lights and loud noise.
  • Cluster headaches often recur regularly, at the same time of day each day, or a week later.
  • Compliance Adherence to a prescribed therapy, including performing an injection according to instructions.
  • Compliance is improved by limiting local effects, and by supplying a injector that is easy to use and doesn't cause fear and anxiety, such as due to needle phobia. Compliance is improved through the use of an injector, preferably an auto-injector, more preferably a needle free injector, which has properties selected from being prefilled, self contained, prefilled, portable, single use, and disposable.
  • an injector preferably an auto-injector, more preferably a needle free injector, which has properties selected from being prefilled, self contained, prefilled, portable, single use, and disposable.
  • Container Closure Container Closure System, and the like: A drug
  • container closure system that is designed to maintain sterility, stability, and eliminate the possibility of contamination of the drug formulation.
  • the container closure system must also have sufficiently low vapor transmission rate such that the concentration of the formulation does not change appreciably over the product shelf life.
  • Preferred materials have sufficiently low leachable materials such that they do not contaminate the formulation during storage.
  • container closure systems include at least one substantially transparent material to allow for inspection of the formulation.
  • Preferred materials for container closures include glass, more preferably borosilicate glass, substantially clear polymers with low water vapor transmission rates including but not limited to cyclo-olefin polymer and copolymers, or fluorinated materials such as polytetrafluoroethylene (PTFE).
  • PTFE polytetrafluoroethylene
  • Container Closure Integrity The ability of a container closure system to maintain sterility, eliminate the possibility of contamination, and minimize loss of carrier during storage.
  • Delivery Phase A constant or slowly varying formulation pressure during which the bulk of a formulation dose is delivered from a needle-free injector.
  • the desired injection is a subcutaneous injection. This in general requires a previous, higher pressure phase (see “puncture phase") wherein the hole through which the injectate is delivered is formed.
  • Depot Injection An injection, usually subcutaneous, intravenous, intradermal, or intramuscular, of a pharmacological agent which releases its active compound in a consistent way over a long period of time. Depot injections may be available as certain forms of a drug, such as decanoate salts or esters. Examples of depot injections include Depo Provera and haloperidol
  • Energy source a component of a drug delivery system, preferably of an
  • actuator of an auto-injector that supplies the energy required for the delivery.
  • Preferred energy sources include mechanical springs, compressed gas, electrical storage such as batteries, and chemically based energy sources including but not limited to pyrotechnic compounds and combustible compounds including but not limited to Butane and Propane. Particularly preferred energy sources are
  • formulations are liquid formulations, including but not limited solutions, suspensions including nano-suspensions, emulsions, polymers and gels.
  • Formulations include but are not limited to those containing excipients that are suitable for injection, and contain one or more active pharmaceutical ingredients. See also "Topical Formulation”.
  • injections can be used to deliver formulations to any tissue, preferred injections go through the skin
  • injections or into the skin (intra-dermal injections).
  • Injector A device for implementing an injection.
  • Local effect an unintended effect of an injection. Local effects include but are not limited to pain, swelling, erythema, bruising, and distortion of the injection pathway.
  • Migraine A neurological disease with many symptoms, the most predominant of which is headache. The headache is often one-sided and pulsating lasts from hours to days, and is often accompanied by nausea and vomiting, a heightened sensitivity to bright lights and noise, and other symptoms. Approximately one third of people who experience migraine get a preceding aura. Migraine may be distinguished from other headache conditions by: 5 or more attacks without aura, or two or more attacks with aura, 4 hours to 3 days in duration, 2 or more of - unilateral location, pulsating quality, moderate to severe pain, aggravation by or avoidance of routine physical activity, and 1 or more accompanying symptoms - nausea and/or vomiting, photophobia, photophobia.
  • migraine migraine
  • the present invention may be applied to other conditions, for example cluster headache, pain, epilepsy, psychosis, hypoglycemia, panic, vaccination, diabetes, counter terrorism, autoimmune disorders, rheumatoid arthritis, lupus, schleradoma, chrones disease, neurological disorders, Alzheimers, multiple sclerosis, psoriasis, growth retardation in children, hepatitis, AIDS, infertility, ulcer, obesity, athsma, COPD, pulmonary fibrosis, osteoporosis, and allergic reactions.
  • a number of biologic ally- active agents would benefit from being delivered using the current invention.
  • This group could consist of (but not limited to) anti-inflammatory agents, antibacterial agents, antiparasitic agents, antifungal agents, antiviral agents, anti-neoplastic agents, analgesic agents, anaesthetics, vaccines, central nervous system agents, growth factors, hormones, antihistamines, osteoinductive agents, cardiovascular agents, bronchodilators, vasodilators, birth control agents and fertility enhancing agents, interferon alpha, growth hormone, and PTH and PTH analogs and fragments
  • Multidose, reusable, and the like Containing enough formulation for and capable of delivering more than one dose, or capable of being refilled.
  • Multidose injectors may deliver a single, pre-determined dose, or may allow for the selection of a dose.
  • Needle-Free Injector Needle-Less Injector, Jet Injector, and the like: an
  • Needle free injectors generally utilize a power source to pressurize a liquid formulation, forcing it out of one or more orifices to create a high velocity jet.
  • the pressurization comprises a low pressure precompression to compress any contained gas in the formulation, a high pressure spike (the "puncture phase") that creates a hole in the target tissue, and a lower pressure “delivery phase” during which the majority of the formulation is delivered.
  • Preferred needle free injectors are prefilled, self contained, single use, and portable.
  • Piston a moveable component that seals one end of a preferably cylindrical container. Pistons are generally used to pressurize material in a container and/or move material in or out of a container.
  • An example of a piston is the drug delivery piston of an injector, for example a needle-free injector that under force from an energy source drives liquid formulation out of an orifice to achieve injection.
  • the injector is a needle free injector which is prefilled with formulation, and the piston then becomes a drug contact surface of the container- closure system.
  • the piston has the
  • the piston comprises PTFE.
  • a retractable element that can be used to create a partial vacuum, preferably in order to hold a drug delivery device in place on the surface of a target organ, pull the surface of the target organ into contact with or proximity to an injection orifice, needle or other delivery
  • Portable capable of being easily transported, for example, in a pocket, purse, or glove compartment.
  • Portable injectors preferably have no linear dimension (length, width, or height) greater than 25 cm, preferably no linear dimension greater than 20 cm, more preferably no linear dimension greater than 15 cm.
  • Portable injectors preferably weigh less than 1 kg, preferably less than 0.5 kg, more preferably less than 0.25 kg, most preferably less than 0.1 kg.
  • Preferred portable injectors are self contained, prefilled, and single use.
  • Prefilled injectors are injectors wherein the formulation is filled into the injector before delivery to an end user, for example by a manufacturer, pharmacy, physician, or the like.
  • prefilled drug capsules are filled prior to delivery to an end user, and may be installed on a multi-dose injector by the end user.
  • Pre-filled injectors or capsules specifically do not require filling at the point of use by the patient or a care giver.
  • Preferred pre-filled injectors are self contained, single use, and portable.
  • Pressure can be measured in units of Pascal (Pa), which is a Newton per square meter. Standard atmospheric
  • pressure at sea level is 1.01325 xlO 5 Pa, or one atmosphere (atm).
  • the injection is a subcutaneous injection.
  • the jet be sufficiently energetic to drill down to the subcutaneum.
  • the bulk of the formulation be delivered at a lower pressure (see “delivery phase"), in order that the formation of the hole is stopped prior to the injection becoming a painful intra-muscular injection.
  • Pump a drug delivery device that deliver a formulation at a controlled rate.
  • Pumps usually deliver through a needle or catheter, but may be needle free or transdermal.
  • the formulation may be delivered through a tubing set, or may attach directly to the skin, sometimes referred to as a "patch pump".
  • Pumps may be somewhat large hospital devices mounted for example on a pole. Preferred pumps are small, discrete and portable.
  • One preferred type of pump is an insulin pump for treatment of diabetes. Pumps may deliver at a preset constant average rate, and/or may have a bolussing feature that allows a single relatively large dose to be
  • Release liner a cover for an adhesive surface that will adhere to the
  • a release liner has a contact surface coated with a release agent with low surface energy that allows it to release from the adhesive, leaving the adhesive intact.
  • Preferred materials include Kraft paper such as super calendared, clay coated, or machine glazed or machine finished Kraft paper, or polymer films, and may
  • polyvinyl alcohol polyvinyl alcohol
  • polyester polypropylene
  • cyclic olefin copolymer cyclic olefin copolymer
  • polychlorotrifluoroethylene and may comprise one or metals including aluminum.
  • Self-Contained containing some or all of the components, materials, energy sources, vacuum sources, etc. that are required for injection.
  • Self contained injectors specifically do not require an external source of energy, such as mains power, or an external source of vacuum. While a self contained injector may require filling with drug formulation prior to delivery, preferred self contained injectors are pre-filled or allow installation of a pre-filled drug capsule.
  • Preferred self-contained injectors are portable. Self contained injectors may be single dose or multi-dose. Preferred multi-dose injectors contain enough energy that the energy source does not have to be re-filled or recharged for the useful lifetime of the device.
  • Spool Valve a valve with a channel and an object movably disposed in the channel (a "spool"), wherein the spool in one position allows a flow, and in another position blocks a flow.
  • Spool valves differ from other valves such as needle or gate valves in that the seal is created by the body of the spool, not around the end of a needle or gate.
  • Spool valves differ from rotary valves such as ball valves in that the when the seal is released the flow occurs around the outside and not through the spool.
  • Spool valves preferably comprise a seal, more preferably, two, three, or more seals.
  • the spool can be any shape, but is preferably substantially a right circular cylinder, with features on the circumference, for example to seat seals or features that allow airflow.
  • the shape of the spool is sufficiently close to shape of the channel that the seals are maintained in sealing contact with the inside walls of the channel.
  • the spool valve of the current invention is configured such that prior to triggering, both ends of the spool communicate with air spaces that are substantially at ambient pressure, and portion of the circumference displaced from both ends is in communication with an air space at a pressure significantly elevated above ambient pressure.
  • the airspaces at ambient pressure may communicate with the outside environment in order to maintain the pressure substantially at ambient pressure, and said communication may be a lead designed to be large relative to any leak from the high pressure source through the spool valve seals, and large enough to substantially maintain the pressure at ambient during any changes in ambient pressure due to weather, temperature change, or altitude change, but small enough to maintain the pressure when the spool valve is actuated and the high pressure material is released.
  • Spring a mechanism capable of storing energy for use in propelling the
  • the mechanism obeys Hooke's law, i.e. the force provided by the energy store is proportional to a displacement.
  • This mechanism may be mechanical, e.g. compressible metal component such as a coil spring or Belleville washer stack.
  • the mechanism is a compressed gas spring in which the energy is stored, and when released the gas expands.
  • Alignment Ring A component of a drug delivery system or kit which has a
  • central bore into which a delivery portion of a drug delivery system is inserted or attached, and a radial flange with a face that contacts an organ, preferably skin, around a desired drug delivery site.
  • the bore of the alignment ring and/or the direction in which the drug is delivered is at a fixed angle to the face, preferably substantially perpendicular to the face, to ensure that the delivery happens at a pre-specified angle.
  • the face is adhered to the target organ for example prior to the insertion of the delivery portion of the drug delivery system by the use of an adhesive, or by the use of a partial vacuum.
  • the alignment ring is movable or deformable, and the motion grips the surface of the target organ, holding the drug delivery device in place, and/or pulling the surface of the target organ toward the drug delivery device, for example onto a needle or in contact with or at a predetermined distance from an orifice, microneedle array or other transdermal source.
  • the Alignment Ring is called a ring, and preferably the shape of the contact area on the target organ is round, it should be noted that any shape of the bore is acceptable, including but not limited to squares, triangles, pentagons, hexagons, or more complex shapes including extensions or legs, preferably three, four or more, as long as it engages an outside surface or feature on the drug delivery system and controls the angle of the drug delivery system relative to the target organ and/or keeps the drug delivery system fixed relative to the target organ during delivery.
  • the Alignment Ring will surround enough of the drug delivery device to maintain the fixed angle and/or position relative to the target organ, and preferably encircles the drug delivery device.
  • the alignment ring encircles the device and injection site in such a way that the patient cannot see the injection site, needle, catheter, needle free injection orifice, etc, and cannot see the act of inerting a needle, catheter, and the like, in order to reduce patient fear and anxiety, and improve patient comfort and compliance.
  • the alignment ring engages a portion of the outside surface of the drug delivery device, but other embodiments are possible, such as ribs that engage the surface along lines, or ribs that engage slots in the surface of the drug delivery device, or similarly ribs on the drug delivery device that engage an inside surface or slots in the alignment ring.
  • the alignment ring may have additional features that interact with the triggering mechanism of the drug delivery device, for example causing the device to trigger only when the alignment ring is in contact, including sealing contact, with the surface of the target organ, a predetermined contact force with the surface of the target organ is achieved, and/or a predetermined distance of the drug delivery device from the target organ, including zero distance, is achieved.
  • Topical Application delivery of a formulation, usually liquid, to the surface of an organ, preferably the skin, usually for local effect.
  • Topical formulation a formulation for topical application.
  • Topical formulations are preferably liquid, and preferably have elevated viscosity, such as 5 or more, 10 or more, 50 or more, 100 or more, 500 or more, 1000 or more, 5000 or more, or 10,000 or more cP or cS.
  • Topical formulations may contain one or more active ingredients such as vasodilators, local anesthetics, and/or anti-microbials, and/or may contain other topical surface preparation agents, such as absorption enhancers, adhesives, vacuum sealing agents, depilatory agents, cleaning agents, and the like.
  • Topical Formulations may comprise one or more local anesthetics, including but not limited to Benzocaine, Chloroprocaine, Cocaine,
  • Cyclomethycaine Dimethocaine, Larocaine, Piperocaine, Propoxycaine, Procaine, Novocaine, Proparacaine, Tetracaine, Amethocaine, Lidocaine, Articaine,
  • Topical formulations may comprise one or more vasoconstricting agents, including by not limited to Epinephrine, 251-NBOMe, Amphetamine, AMT, Antihistamine, Caffeine, Cocaine, DOM, LSA, Methylphenidate, Mephedrone, Oxymetazoline, Phenylephrine, Propylhexedrine, Pseudoephedrine, Tetrahydrozoline hydrochloride, and/or combinations, conjugates, prodrugs, or fragments thereof.
  • vasoconstricting agents including by not limited to Epinephrine, 251-NBOMe, Amphetamine, AMT, Antihistamine, Caffeine, Cocaine, DOM, LSA, Methylphenidate, Mephedrone, Oxymetazoline, Phenylephrine, Propylhexedrine, Pseudoephedrine, Tetrahydrozoline hydrochloride, and/or combinations,
  • Topical formulations may comprise one or more absorption and/or dispersion enhancing agents, including but not limited to Hyaluronic Acid, Chitosan, an Alkylsaccharide, A Surfactant, Laureth Benzote, Laureth acetate, and/or combinations, conjugates, prodrugs, or fragments thereof.
  • absorption and/or dispersion enhancing agents including but not limited to Hyaluronic Acid, Chitosan, an Alkylsaccharide, A Surfactant, Laureth Benzote, Laureth acetate, and/or combinations, conjugates, prodrugs, or fragments thereof.
  • Topical formulations may comprise one or more anti-microbials, including but not limited to an anti-bacterial such as a penicillin, a cephalosporin, a polymyxin, a rifamycin, a lipiarmycin, a quinolone, a sulfonamide, a macrolide, a lincosamide, a tetracycline, an aminoglycoside, a cyclic lipopeptide, a glycylcycline, a oxazolidinone, and/or a lipiarmycin; Anti-fungals including an Imidazole, a triazole, a thiazole, an allylamine, an echinocandin, benzoic acid, ciclopirox, flucytosine, griseofulvin, haloprogin, polygodial, tolnaftate, undecylenic acid and/or crystal violet; an anti-viral; and/or an anti-parasitic.
  • Preferred active pharmaceutical agents in Topical Formulations include but are not limited to Benzocaine, Lidocaine, Tetracaine, Hyaluronic Acid, Epinephrine, and/or combinations, conjugates, prodrugs, or fragments thereof.
  • Transdermal Delivery of a formulation or API by absorption or diffusion through the skin, or a drug delivery system for achieving delivery by absorption or diffusion through the skin.
  • the absorption of the drug may be passive, or may be enhanced by the use of electric current, micro-needle arrays, sound, radio frequency and other electromagnetic power, lasers, permeation enhancers, heat, etc.
  • Injection, and specifically needle free injection although often used to deliver formulation through the skin, is specifically not considered to be transdermal delivery.
  • Triptan Tryptamine based drugs used for the treatment of migraine and cluster headaches. They are 5-HT1 (serotonin) receptor agonists. They bind to 5- HT1B and 5-HT1D receptors in blood vessels, causing constriction and subsequent inhibition of pro-inflammatory neuropeptide release. Additionally they act on serotonin receptors in nerve endings, decreasing the release of several peptides, including CGRP and Substance P. Triptans include but are not limited to sumatriptan (Imitrex, Imigran), rizatriptan (Maxalt), naratriptan (Amerge,
  • triptan is also meant to include other forms such as salts, esters, active fragments, analogues and other forms of these drugs, as well as Tryptamine based drugs that may be developed in the future
  • Vacuum, Partial Vacuum, and the like a reduction in gas pressure relative to the surrounding ambient air.
  • Vacuum cup a device or type of alignment ring attached to an injector that uses a supplied vacuum to seal a drug delivery device to the skin, and thereby ensure that the injector does not move and is held at a predetermined angle, preferably perpendicularly, to the target organ or skin.
  • the vacuum cup pulls the skin into the cup, holding it against or at a fixed distance to one or more orifices, microneedle arrays, transdermal sources, or pulls the skin onto a needle or catheter, and stretches and tensions the skin to prepare it for, for example, needle free injection.
  • Preferred vacuum pressures are less than 100 kPa, preferably less than 75 kPa, more preferably less than 50 kPa.
  • the injector comprises an actuator with a trigger, and the trigger is interlocked to the vacuum in the vacuum cup, ensuring that the device cannot trigger unless the vacuum cup is sealed to the target organ or skin and a pre-determined vacuum is applied. Still more preferably, the vacuum directly actuates the trigger.
  • the applied vacuum is less than ambient pressure, preferably less than 90% of ambient pressure, more preferably less than 75% of ambient pressure, more preferably less than 50% of ambient pressure.
  • WVTR Water Vapor Transmission Rate
  • Figure 1 shows one embodiment of the current invention which is a needle free, self contained, portable, prefilled, single use, and disposable auto-injector.
  • the medical device is a drug delivery system
  • the treatment site is a delivery site.
  • drug delivery systems include but are not limited to needles, catheters, pumps, infusion system, bolus injectors, passive transdermals such as patches, and active transdermals including but not limited to transdermals enhanced by radio frequency, lasers and other light sources, heat, sound, electrical current, etc.
  • Other devices that do not deliver drugs may include sensors, stimulators, surgical tools and the like.
  • needle free injector 1 is equipped with actuator
  • first formulation reservoir 10 which contains a first formulation and is sealed by a piston, injection orifice or orifices 8, and cap/applicator 6.
  • Actuator 11 includes a source of power for supplying the energy needed to the injection.
  • the source of power can be any compact portable power source including but not limited to batteries, a mechanical spring, or a pyrotechnic or combustion source.
  • the source of power is a gas container which holds a pressurized gas.
  • Actuator 11 also includes a trigger to release the power from the power source, a safety mechanism to ensure the injector is not triggered prematurely, and a transmission mechanism that creates the desired pressure profile as a function of time in the first formulation reservoir.
  • the transmission mechanism includes a ram which is initially separated from the piston by an air gap.
  • the pressurized gas acts directly on the ram, and the piston acts directly on the first formulation.
  • Actuator 11, first formulation reservoir 10, and cap/applicator 6 may be filled, charged, and assembled in a factor setting and delivered to a customer substantially as shown as a single use disposable unit.
  • actuator 11 maybe a muli-use component.
  • first formulation reservoir 10 and cap/applicator 6 are factory filled and assembled as a single unit to be attached to actuator 11 prior to use.
  • cap/applicator 6 is removed.
  • Cap/applicator 6 can be removably attached to injector 1 in many ways, including but not limited to screw off, a bayonet fitting, snap off, twist off, or pull off.
  • Needle free injector 1 can be triggered by many means, including but not limited to pushing a button or actuating a lever or a slide. Preferably needle free injector 1 is triggered by pushing nozzle 8 against the desired injection site, i.e. a target organ or the skin.
  • injector 1 is supplied with a safety mechanism.
  • the safety mechanism is put in the ready to fire state by rotating lever 3 around axis 2.
  • Lever 3 comprises tip 4 which is captured under a lip of cap/applicator 6, ensuring that the injector cannot be placed in the ready to fire state until after cap/applicator 6 is removed.
  • injector 1 is triggered by pressing injection orifice 8 against the desired injection site, and does not include lever 3.
  • cap/applicator 6 is attached to drug reservoir 10 via a first set of threads.
  • Injector 1 including reservoir 8 is at least partially surrounded by a housing, which the user grips during delivery.
  • Cap/applicator 6 is also attached to a housing (not shown) via a second set of threads.
  • the first set of threads and the second set of threads are configured such that the act of removing cap/applicator 6 by unscrewing it biases drug reservoir relative to the casing in a direction opposite that required to trigger the device, i.e. downward when in the orientation shown in Fig. 1. This prevents the possibility of the act of removing cap/applicator 6 causing injector 1 to trigger.
  • Orifice seal 23 as shown in Figure 2b comprises a suitable sealing material, which is preferably a compliant material. Additional preferred properties for orifice seal 23 are low WVTR, low leachables, high dimensional stability (low creep), and compatibility with drug formulations including small molecule and large molecule (peptide and protein) formulations.
  • cap/applicator 6 is removed by unscrewing, and orifice seal 23 may be supplied with an optional rotating mechanism to avoid stress and concomitant loss of seal when cap/applicator 6 is installed.
  • Cap/applicator 6 includes second formulation 22 in reservoir 5. Second
  • formulation 22 preferably has one or more APIs which are indicated for avoiding local effects including but not limited to pain, bleeding, swelling, erythema, infection, and bruising, and is formulated for topical application.
  • second formulation reservoir 5 may contain non-active ingredients, including but not limited to adhesives, vacuum sealing agents, cleaning agents, and/or depilatory agents.
  • Second formulation 22 may comprise a local anesthetic, including but not limited to Benzocaine, Chloroprocaine, Cocaine, Cyclomethycaine, Dimethocaine, Larocaine, Piperocaine, Propoxycaine, Procaine, Novocaine, Proparacaine,
  • a local anesthetic including but not limited to Benzocaine, Chloroprocaine, Cocaine, Cyclomethycaine, Dimethocaine, Larocaine, Piperocaine, Propoxycaine, Procaine, Novocaine, Proparacaine,
  • Tetracaine Amethocaine, Lidocaine, Articaine, Bupivacaine, Cinchocaine,
  • Dibucaine Dibucaine, Etidocaine, Levobupivacaine, Lidocaine, Lignocaine, Mepivacaine, Prilocaine, Ropivacaine, Trimecaine, and/or combinations, conjugates, prodrugs, or fragments thereof.
  • Second formulation 22 may comprise a vasoconstricting agent, including by not limited to Epinephrine, 251-NBOMe, Amphetamine, AMT, Antihistamine, Caffeine, Cocaine, DOM, LSA, Methylphenidate, Mephedrone, Oxymetazoline, Phenylephrine, Propylhexedrine, Pseudoephedrine, Tetrahydrozoline
  • a vasoconstricting agent including by not limited to Epinephrine, 251-NBOMe, Amphetamine, AMT, Antihistamine, Caffeine, Cocaine, DOM, LSA, Methylphenidate, Mephedrone, Oxymetazoline, Phenylephrine, Propylhexedrine, Pseudoephedrine, Tetrahydrozoline
  • hydrochloride and/or combinations, conjugates, prodrugs, or fragments thereof.
  • Second formulation 22 may comprise an absorption and/or dispersion
  • enhancing agent including but not limited to Hyaluronic Acid, Chitosan, an
  • Alkylsaccharide A Surfactant, Laureth Benzote, Laureth acetate, and/or
  • Second formulation 22 may contain an anti-microbial, including but not
  • an anti -bacterial such as a penicillin, a cephalosporin, a polymyxin, a rifamycin, a lipiarmycin, a quinolone, a sulfonamide, a macrolide, a lincosamide, a tetracycline, an aminoglycoside, a cyclic lipopeptide, a glycylcycline, a
  • Anti-fungals including an Imidazole, a triazole, a thiazole, an allylamine, an echinocandin, benzoic acid, ciclopirox, flucytosine, griseofulvin, haloprogin, polygodial, tolnaftate, undecylenic acid and/or crystal violet; an anti- viral; and/or an anti-parasitic.
  • Preferred active pharmaceutical agents in second formulation 22 include but are not limited to Benzocaine, Lidocaine, Tetracaine, Hyaluronic Acid,
  • Epinephrine and/or combinations, conjugates, prodrugs, or fragments thereof.
  • cap/applicator 6 has a single second formulation reservoir 5, the cap may contain multiple reservoirs 5 containing multiple formulations 22 and/or surface preparation compounds. In this way non- compatible compounds can be stored in a stable manner.
  • Cap/applicator 6 may include one or more nozzles 7 for the delivery of second formulation 22 in second formulation reservoir 5.
  • second formulation 22 preferably has elevated viscosity of greater than 10 cP, preferably greater than 100 cP, more preferably greater than 1000 cP.
  • nozzle 7 comprises a material or coating which is hydrophobic, lipophobic, or has similar properties to avoid wicking of the second formulation.
  • a coating may be applied by many methods, including but not limited to plasma coating.
  • nozzle 7 may be fabricated such that the exit is normally closed, and second formulation 22 must be pressurized to open the end of nozzle 7 and extrude second formulation 22.
  • second formulation 22 and nozzle 7 have 2 or more of the above properties to avoid leaking and dripping.
  • Nozzle 7 may have a cover (not shown) that is used to maintain container closure integrity, which cover is removed by the user immediately prior to the topical application of second formulation 22.
  • the cover may be a release liner that is adhered to the exterior of cap/applicator 6 and covers nozzle 7.
  • Preferred release liners may include multiple layers, including but not limited to a polymer layer and a metallic layer.
  • Preferred polymers include polyethylene, polyester, nylon, cyclic olefin copolymer, and polychlorotrifluoroethylene, and metals include aluminum.
  • nozzle 7 does not have a separate cover, but is sealed to the outside of drug reservoir 10 as shown in figure 1 to maintain container closure integrity of second formulation reservoir 5 during storage.
  • Nozzle or Nozzles 7 and injection orifice 8 can in general be in any location, although in general they cannot be aligned, in order to avoid mixing of the first and second formulations.
  • orifice 8 is on the central axis of injector 1, and nozzle 7 is displaced from the central axis of injector 1.
  • Cap/applicator 6 may optionally comprise a mechanism (not shown) to
  • APIs in second formulation 22 include but not limited to mechanical enhancement using a needles or needles, micro-needle arrays, brushes including wire brushes, or abrasives.
  • Cap/applicator 6 may optionally comprise a mechanism (not shown) to
  • cap/applicator 6 preferably comprises a self contained power source and a mechanism for releasing the energy.
  • Figure 2 shows the operation of the embodiment of cap/applicator 6 of
  • Figure 1 shows cap/applicator 6 after removal from injector 1.
  • Figure 2b shows a cross section of cap/applicator 6, including second formulation 22 contained within second formulation reservoir 5, and side walls 21.
  • Figure 2c shows the topical application of second formulation 22 using cap/applicator 6 of the current invention.
  • Cap/applicator 6 is removed from injector 1 by an action chosen from a list including but not limited to snapping it off, pulling it off, twisting it off, twisting followed by pulling, or preferably by unscrewing.
  • An optional cover (not shown) is removed and discarded. This exposes orifice 8 and nozzle or nozzles 7.
  • the user selects a site, preferably an injection site, on organ 29, which is preferably skin. Holding cap/applicator 6 by walls 21 using thumb 27 and finger 28, the open end of cap/applicator 6 is applied to the selected site on organ 29, and walls 21 are pressed inwardly. This creates an elevated pressure in second formulation 22, forcing it out of nozzle 7.
  • Cap/applicator 6 is optionally moved laterally across the surface of organ 29, spreading second formulation 22 over a desired area. After second formulation 22 is applied, cap applicator 6 is discarded. Other means of delivering second formulation 22 may be used, including but not limited to pressing an actuator such as a plunger, pushrod, lever, or the like.
  • the prescribed wait time may be 0 seconds (i.e. no wait time) but is preferably 30 seconds or more, more preferably 1 minute or more, 5 minutes or more, or about 10 minutes.
  • optional lever 3 is rotated to put injector 1 in the ready state.
  • injection orifice 8 is then pressed against the desired injection site until injector 1 triggers.
  • Injector 1 (or in the embodiment where actuator 11 is a multi-use
  • first formulation reservoir 10 which is detached by the user
  • the injection site is cleaned, treated, bandaged, and/or pressure is applied as required.
  • FIG. 3 shows an additional embodiment that may be combined with the embodiment shown in Figures 1 and 2.
  • injector 1 is supplied as part of a kit that also includes alignment component or "alignment ring" 31.
  • Alignment ring 31 can be of any shape, but is preferably round in cross section. Some or all of the shape of interior region 35 of alignment ring 31 preferably matches some or all of the exterior shape of injector 1.
  • Alignment ring 31 is placed in contact with organ 28, preferably skin, at a desired delivery site, and optionally held in place using adhesive 32.
  • Alignment ring 31 comprises radial extension 33. Radial extension 33 supplies a surface or face with which to adhere alignment ring 31 to target organ 28.
  • radial extension 33 serves to ensure that wall 34 of alignment ring 31 holds the central axis of injector 1 and/or orifice 8 at a fixed angle to the surface of organ 28, preferably perpendicular to organ 28 as shown in figure 3. In this way alignment ring 31 ensures that injector 1 is held at the correct orientation to organ 28 and does not move relative to organ 28, eliminating the possibility of distortion of the injection path into or through organ 28 and ensuring that the injection is to the desired depth in or through organ 28.
  • alignment ring 31 is configured in such a way that it substantially encircles the delivery site and/or component of the injector, for example a needle, catheter, injection orifice, and the like, such that the patient cannot see it during the delivery process, thereby reducing patient anxiety and fear, and improving patient comfort and compliance.
  • the injector is a needled injector, and the patient cannot see the needle or the act of insertion of the needle into the target organ.
  • Adhesive 32 may be supplied separately from alignment ring 31, for example as a liquid with an applicator, or as an adhesive tape.
  • the adhesive is contained in and applied using the cap/applicator described above and shown in figures 1 and 2. More preferably, the adhesive is a double sided adhesive tape which is fabricated, for example die cut, to cover some or all of the front face of radial extension 33 of alignment ring 31, is factory adhered to the front face, and is supplied with a release liner that is removed prior to applying alignment ring 31 to organ 28.
  • the release liner may cover front opening 36, and is preferably the same shape as adhesive 32 to facilitate fabrication, possibly with the addition of a tab or other feature that extends beyond adhesive 32 to facilitate removal.
  • the release liner may be attached to or comprise packaging, and removal of alignment ring 31 from the packaging removes the release liner.
  • Adhesive 32 may also contain one or more APIs for the reduction of local effects, including but not limited to pain, bleeding, swelling, infection, bruising, and/or erythema.
  • the adhesive is only applied to the front face of radial extension 33, and not in front opening 36 of central bore 35 of alignment ring 32, leaving opening 36, through which the injection occurs, clear of adhesive.
  • adhesive 32 covers front opening 36, and the injection occurs through adhesive 32. This embodiment is preferred in those embodiments that include an API in the adhesive that is preferably applied directly to the injection site.
  • adhesive 32 does not cover front opening 36, but front opening 36 is filled with a second formulation in a form including but not limited to a liquid, gel, powder, solid, or gas.
  • Alignment ring 31 and injector 1 may be supplied together as part of a kit, with optional components selected from labels, cleaning swabs or cloths, instructions including written instructions, audio instructions, and/or video instructions, dosing logs, dosing reminders, timers, razors, adhesives, second drug formulation containers and applicators, bandages, etc, and the kit and or components may be packaged in one or more boxes, overwraps, secondary packages, or tertiary packages.
  • instructions may be supplied by an external electronic device, including but not limited to a smart phone, tablet, computer, wrist watch, or eye glasses.
  • the packaging may also be used to hold the injector, alignment ring, and/or other components after use until they can be safely disposed of, for example in a sharps container when the injector comprises a needle.
  • adhesive 32 or other components such as a topical formulation applicator have a release liner
  • the release liner may be attached to the packaging, and the act of removing them from the packaging also removes the release liner, for example exposing adhesive 32.
  • alignment ring 31 and injector 1 may be used as follows. Alignment ring 31 is removed from its packaging, and a release liner is removed, exposing adhesive 32. Adhesive 32 is pressed onto target organ 28, preferably the skin of a human or animal patient, with opening 36 surrounding the target injection site. If required, the user waits for a specified wait time, for example for adhesive 32 to cure or for an API in adhesive 32 to take effect. A cap is removed from injector 1, and injector 1 is optionally placed in a ready to inject state, for example by rotating optional lever 3. Injector 1 is then placed in central bore 35 of alignment ring 31 and injection orifice 8 is pressed against organ 28, triggering injector 1. Injector 1 is then disposed of, and alignment ring 31 is removed from organ 28 and disposed of.
  • Alignment ring 31 may be supplied attached to injector 1, and function as the cap for orifice 8. Alignment ring 31 may comprise features that interface and actuate mating features on injector 1. These mating features may be a safety mechanism that only allows injector 1 to be triggered if inserted in alignment ring 31. Similarly, the mating features may directly actuate the trigger of injector 1, for example when orifice 8 is at a
  • the kit may contain multiple injectors 1, which may contain the same or different formulations. While alignment ring 31 is preferably single use and
  • Alignment ring 31 may be fabricated by many methods, including but not limited to injected molding, machining, lithography, or 3D printing. Alignment ring 31 can be fabricated using many materials, including but not limited to polymers, metals or glasses. Preferably alignment ring 31 is an injected molded polymer part. Preferred polymers include but are not limited to polycarbonates, nylons, poly ethylenes, polypropolenes, polyolefins, polyvinylchlorides, and ethylene vinyl acetates.
  • FIG. 4 shows another embodiment of the invention.
  • drug delivery device 1 is a needle free injector that is powered by compressed gas source 109.
  • Compressed gas source 109 is sealed by, and when the injector 1 is triggered, gas in compressed gas source 109 is released by a spool valve comprising spool 105.
  • Injector 1 comprises vacuum source 104.
  • injector 1 comprises vacuum cup 108.
  • Vacuum cup 108 extends radially from injector 1, and when pressed against an organ of a user, preferably skin, vacuum cup 108 acts as an alignment ring, ensuring that injector 1 is held at a preferred angle relative to the organ.
  • vacuum cup 108 ensures that injector 1 is held perpendicular to the surface of the target organ, but may be modified to ensure that injector 1 is at any angle relative to the target organ appropriate to the type of injector, desired depth of injection, active pharmaceutical ingredients, and/or target organ.
  • Vacuum source 104 communicates with spool 105 and vacuum cup 108 via vacuum plenum 106.
  • Spool 105 is optionally held in place by safety 107, which is connected to piston 103 or lever 101, and moves upward when lever 101 is actuated, presenting a path for spool 105 to move toward or into vacuum plenum 106.
  • the applied vacuum pulls the surface of the target organ, preferably skin, into vacuum cup and to a fixed distance from, preferably tightly against, injection orifice 8. This ensures that the target organ is stretched in the region of orifice 8 and preferably in contact with orifice 8 to ensure a successful needle free injection. This also obviates the need to prepare the target organ, for example skin, by pinching a fold of the surface for injection.
  • the applied vacuum also ensures that injector 1 does not move during injection, reducing the possibility of distortion of the injection path.
  • the injector trigger preferably requires the vacuum to be present in vacuum cup 108 in order to trigger the device, preventing premature firing and further reducing the possibility of injection path distortion.
  • the front surface of vacuum cup 108 is somewhat non-planar, so that the device cannot be triggered by pressing against a flat, non-compliant surface like a table top.
  • the volume of vacuum plenum 106 and vacuum cup 108 (when sealed to the target organ) is minimized. This allows for minimization of the required travel of lever 101. It also allows for the minimization of the area of vacuum piston 103, minimizing the force that must be applied to lever 101,
  • the combined volume of vacuum plenum 106 and vacuum cup 108 is less than 20 cc, more preferably less than 10 cc, still preferably less than 5 cc, most preferably less than 3 cc.
  • the required force on lever 101 is less than 50N, more preferably less than 25N, still more preferably less than 10N, most preferably about 5N or less.
  • vacuum plenum 106 is fabricated of tubing with the minimum diameter that will not substantially impede the flow of air from vacuum cup 108 to vacuum source 104.
  • the inside diameter of the tubing is less than 10 mm, preferably less than 5 mm, more preferably less than 2.5 mm, most preferably about 1 mm or less.
  • the sealing medium can be any medium that improves the seal and is acceptable for contact with the target organ, including but not limited to greases, petroleum jellies, emollients, lotions, moisturizers, gels, ultrasound coupling media, and the like.
  • the sealing medium is preferably of elevated viscosity, preferably more than 10 cP, more preferably more than 100 cP, most preferably more than 1000 cP.
  • the sealing medium may be contained within vacuum cup 108 and is covered by the orifice cap (not shown) prior to use.
  • the sealing medium is packaged in and applied with a cap/applicator as previously described.
  • the seal may be provided by the properties and material of vacuum cup 108, for example making it flexible, or may be provided by an additional component around the rim, preferably over- molded onto the rim, that is compliant and provides a good seal, for example a rubber component.
  • vacuum cup 108, vacuum source 104, vacuum plenum 106 and injector 1 are preferably integrated at a factory and form a unified drug delivery system that is self contained, portable, prefilled, single use, and disposable.
  • injector 1 is prefilled, single use, and disposable, and vacuum cup 108, vacuum source 104, and vacuum plenum 106 form a separate, multi-use device into which injector 1 is installed prior to use.
  • vacuum cup 108, vacuum source 104, vacuum plenum 106 and injector 1 are integrated into a durable, multi-dose device, which is either filled prior to use by filling drug reservoir 113 or replacing drug reservoir 113, or wherein drug reservoir 113 contains multiple doses.
  • vacuum cup 108, drug reservoir 113, and piston 112 are a factory integrated and filled single use disposable component that is attached to the other components of injector 1, which are multi-use, prior to delivery.
  • injector 1 can be replaced by any type of drug delivery device that requires controlled placement relative to a target organ, including but not limited to needled injectors, catheters, transdermal systems, gene therapy delivery systems, pumps, bolus injectors, and the like.
  • injector 1 is a needled injector or pump with a retractable needle or catheter, and when lever 101 is actuated, more preferably only when there is a predermined partial vacuum in vacuum cup 108, the needle or catheter is inserted and delivery commenced.
  • lever 101 will return to its initial position when released under the urging of spring 102. This allows for an immediate additional attempt if a seal of vacuum cup 108 to the target organ is not achieved, whereby the user removes vacuum cup 108 from the target organ, releases lever 101, repositions vacuum cup 108 against the target organ, and again actuates lever 101.
  • Preferred high volume and/or high viscosity formulations include protein formulations, peptide formulations, high concentration low molecular weight formulations, sustained release formulations including depots, and other controlled release formulations.
  • lever 101 For extended duration deliveries, it will be preferable for lever 101 have a feature such as a detente to lock it in place in the actuated position.
  • a feature such as a detente to lock it in place in the actuated position.
  • the detente or other locking mechanism is not active unless a predetermined partial vacuum is achieved.
  • Figure 5a shows a detailed view of the spool valve.
  • FIG. 5a shows a detailed view of the spool valve.
  • spool 105 has three seals, preferably o-ring seals: first seal 136, second seal 137, and third seal 130. Stop 141 limits the travel of spool 105 when injector 1 is triggered.
  • First seal 136 isolates volume 135 from the high pressure gas of compressed gas source 109, which communicates with spool 105 in the region between first seal 136 and second seal 137 via gas conduit 133. It is important that volume 135 be maintained at ambient pressure so that there is no net force on spool 105 until a partial vacuum exists in vacuum plenum 106. Accomplish this, volume 135 communicates with the ambient air via leak 134.
  • the size of leak 134 is chosen such that it is larger than any leak through seal 136, and is large enough that volume 135 is largely maintained at ambient pressure during any changes in weather, temperature, or altitude. The size of leak 134 is small enough that no appreciable loss of pressurized gas occurs when injector 1 is triggered.
  • leak 134 is non-sealingly covered, for example by injector casing 138, so that leak 134 does not become obstructed.
  • Second seal 137 isolates headspace 139 from the high pressure gas of compressed gas source 109, which communicates with spool 105 in the region between first seal 136 and second seal 137 via gas conduit 133. It is important that headspace 139 be maintained at ambient pressure so that there is no net force on ram head 110 until injector 1 is triggered. To accomplish this, headspace 139 communicates with the ambient air via leak 131.
  • the size of leak 131 is chosen such that it is larger than any leak through seal 137, and is large enough that headspace 139 is largely maintained at ambient pressure during any changes in weather, temperature, or altitude. The size of leak 131 is small enough that no appreciable loss of pressurized gas occurs when injector 1 is triggered.
  • Third seal 130 ensures that headspace 139 does not communicate with vacuum plenum 106 so that vacuum source 104 does not have to evacuate head space 139.
  • head space 139 is small enough that it can be easily evacuated by vacuum source 104 without appreciably changing the amount of travel required of lever 101.
  • Third seal 130 is eliminated, as is leak 131.
  • upon triggering of injector 1 spool 105 preferably travels far enough that second seal 137 traverses conduit 132, sealing the now pressurized gas of headspace 139 from vacuum plenum 106.
  • injector 1 of the embodiment of figures 4 and 5 is as follows:
  • the user removes a cap (not shown) that covers orifice 8.
  • the cap may be a simple cover for orifice 8 and an optional sealing medium (not shown) that has been previously applied to vacuum cup 108, but preferably is cap/applicator 6 as described relative to Figures 1 - 2.
  • the user applies a second formulation using cap applicator 6, discards cap/applicator 6, and waits for a pre-specified wait time.
  • cap/applicator 6 contains a vacuum sealing medium to ensure a good seal of vacuum cup 108 to the surface of a target organ.
  • Injector 1 is then gripped between the fingers and palm near the top in such a way that the thumb extensibly contacts lever 101.
  • Vacuum cup 108 is placed in contact with the target organ, preferably the skin, and the thumb is extended, actuating lever 101.
  • the actuation of lever 101 causes vacuum piston 103 to move upward, drawing air from vacuum plenum 106 and simultaneously translating safety 107.
  • vacuum cup 108 is in sealing contact with the target organ, a partial vacuum is created in vacuum plenum 106 and vacuum cup 108.
  • the partial vacuum in vacuum cup 108 pulls the skin up into firm contact with injection orifice 8 and stretches the skin, preparing it for injection.
  • FIG. 5b shows the spool valve in this post triggered state, and shows flow path 140 whereby the pressurized gas from gas reservoir 109 flows into headspace 139 from high pressure inlet 133 to conduit 132. This flow pressurizes headspace 139, creating a force on ram head 110 of ram 111.
  • ram 111 moves downward and strikes piston 112. This causes a pressure spike in formulation 113, forcing a portion of formulation 113 out of injection orifice 8 and forming a hole into the target organ to a predetermined depth. Under the continued urging of the pressurized gas, the remainder of formulation 113 is delivered out of orifice 8 and through the previously formed hole.
  • FIG. 6 Another embodiment of the topical drug applicator is shown in Fig. 6.
  • Cup 200 and cover 202 contain the topical drug formulation, which is infused into compliant, absorbent element 201, which is preferably a sponge.
  • compliant, absorbent element 201 which is preferably a sponge.
  • the user grips cup 200 with one hand and then bends tab 203 until it separates from cup 200. This is the state shown in 203.
  • the user then peels off and disposes of cover 202.
  • Drug infused compliant element 201 then expands to extend outside cup 200, as shown in Fig. 6b.
  • the user presses and/or rubs the now exposed compliant element 201 against a desired site on a target organ or skin.
  • the pressing and/or rubbing is optionally combined with squeezing of cup 200, much as is shown in Fig. 2c. At this point the topical applicator is disposed of.
  • the topical applicator of Fig. 6 may be a standalone item, or may be supplied as a multiplicity of identical applicator in a box, bag, or other package, with instructions for use and additional information that may comprise an expiry date, drug contents, drug strength(s).
  • the topical applicator of Fig. 6 is supplied as part of a kit with a drug delivery device, preferably an injector, and additional items as described above and below.
  • the topical applicator of Fig. 6 may be combined with additional functionality, for example a cap for drug delivery device, including but not limited to a needle cap or an orifice cap.
  • cover 202 is attached to another component, for example a drug delivery device or a package, and the act of detaching the topical applicator from the other component also removes cover 202.
  • Figure 7 shows another embodiment of the invention, related to that shown in figure 4. This embodiment, similarly to that shown in figure 4, comprises drug delivery device 1 powered by compressed gas source 109, a spool valve comprising spool 105, vacuum source 104, vacuum cup 108, injection orifice 8, and vacuum plenum 106.
  • the embodiment of figure 7 comprises movable housing 116 which is connected to piston 103 via push rod 115.
  • the user grips movable housing 116 and presses vacuum cup 108 and orifice 8 against the desired injection site.
  • vacuum cup 108 is firmly seated against the target organ, additional user force will cause movable housing 116 to move downward relative to drug delivery device 1.
  • This downward movement causes push rod 115 to push piston 103 downward against return spring 102, creating a partial vacuum in the volume of vacuum source 104 above piston 103, vacuum plenum 106 and vacuum cup 108 if and only if vacuum cup 108 is sealed to the surface of the target organ.
  • Damping medium 117 is provided between moveable housing 116 and a component locked rigidly to drug delivery device 1 (shown here as vacuum plenum 106) in order to avoid recoil of drug delivery device 1 when it is triggered.
  • Any suitable damping mechanism can be used, preferably damping or kilopoise grease.
  • the system may include a trigger safety mechanism (not shown) similar to safety 107 shown in figure 4, with an aperture into which spool 105 can move when the safety moves downward. The additional details of the operation are the same as in Figure 4 as described above.
  • Figure 8 shows another embodiment of the invention, related to that shown in figure 4.
  • This embodiment similarly to that shown in figure 4, comprises drug delivery device 1 powered by compressed gas source 109, a spool valve comprising spool 105, and injection orifice 8.
  • Alignment ring 108 now has the ability to grip the surface of the target organ, and deform, rotate, or otherwise move in order to create an injection platform on the surface of target organ 29, pulling the desired injection site on target organ 29 into proximity or preferably contact with orifice 8. In this way it is ensured that target organ 29 is prepared for delivery by pulling up and stretching the surface of target organ 29, bringing the target injection site on organ 29 into proximity or contact with orifice 8, and ensuring that the target injection site does not move during the injection. Alignment ring 108 is moved by any suitable means. In the embodiment shown in figure 8, alignment ring 108 is deformed by pressing on lever 101, preferably with the thumb while gripping drug delivery device 1 with the fingers.
  • Alignment ring 108 can be constructed of any suitable material or materials.
  • alignment ring 108 is substantially rigid, and includes features such as a hinge or hinges that allow for the deformation shown in figure 8b.
  • cup 108 may be fabricated of a compliant material and is elastically deformed. The edges of cup 108 are fabricated of a material and in a shape that is capable of gripping the surface of the target organ, and if required, creating a vacuum seal. This material may be used for the entirety of alignment ring 108, which may then function similarly to a suction cup, or may be a different material that is, for example, over-molded onto the body of alignment ring 108.
  • Element 115 is shown as a push rod. In an alternate embodiment, element 115 may take the form of a cylinder which encircles drug delivery device 1, and contacts alignment ring 108 substantially in a circle.
  • kit which may contain components selected from a delivery device, a first drug formulation containing one or more systemically active drugs, labels, a topical drug applicator, a second drug formulation containing one or more topical drugs and/or surface preparation agents, an alignment ring, cleaning swabs or cloths, instructions including written instructions, pictures, audio instructions, and/or video instructions, a dosing log, a dosing reminder, a timer, a compliance monitor, a razor, an adhesive, a bandage, etc.
  • the kit may contain a plurality of any of the components.
  • the kit and or components may be packaged in one or more containers, boxes, overwraps, secondary packages, or tertiary packages.
  • the drug delivery device is preferably an injector, more preferably an auto-injector, still more preferably a needle free injector, most preferably a prefilled, single use disposable, portable, compact, self contained needle free auto-injector.
  • the first and/or second drug formulation(s) may be separately packaged in a container, and then inserted, injected, or otherwise loaded into or attached to the drug delivery device prior to use, with or without its container.
  • the first drug formulation is factory loaded into the drug delivery device.
  • the second drug formulation may be separately packaged and then applied to the topical drug applicator by the user prior to delivery.
  • the second drug formulation is factory packaged in the topical drug applicator, which includes a cover or overwrap that ensures the stability and sterility of the topical drug formulation.
  • the topical drug applicator may be separate from the drug delivery system.
  • the topical drug applicator is attached to the injector; more preferably has an additional function, most preferably also functions as a cap or cover for the drug delivery device.
  • the kit contains a factory prefilled, single use disposable, self contained, portable, needle free auto-injector, and the topical drug applicator also functions as the orifice cap for the needle free injector.
  • the first drug formulation, first drug formulation container, second formulation, cap/applicator, and piston are supplied separately as a factory prefilled and assembled single use disposable component, to be attached to a multi-use actuator prior to use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne des appareils et des méthodes permettant de préparer un site d'injection sur un organe cible pour améliorer l'administration d'un médicament. Dans un mode de réalisation, un dispositif d'administration pharmacologique, par exemple un injecteur, est fourni dans un kit avec un applicateur pour une administration topique de médicaments, notamment des anesthésiques, des vasodilatateurs et/ou des amplificateurs d'absorption. L'applicateur peut être associé à une autre fonction, par exemple une aiguille ou un bouchon d'orifice. Dans un autre mode de réalisation, le système d'administration est fourni avec une bague d'alignement, un dispositif de préhension, ou une ventouse pour être sûr que le dispositif d'administration soit en contact avec et au niveau de l'angle souhaité par rapport à l'organe cible, et qu'il immobilise le dispositif d'administration par rapport au site d'administration pendant l'administration. L'invention concerne également des applicateurs topiques et des préparations topiques.
PCT/US2015/024118 2014-04-02 2015-04-02 Kits de préparation de sites d'administration d'un médicament Ceased WO2015153900A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974210P 2014-04-02 2014-04-02
US61/974,210 2014-04-02

Publications (1)

Publication Number Publication Date
WO2015153900A1 true WO2015153900A1 (fr) 2015-10-08

Family

ID=54241294

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2015/024118 Ceased WO2015153900A1 (fr) 2014-04-02 2015-04-02 Kits de préparation de sites d'administration d'un médicament
PCT/US2015/024116 Ceased WO2015153899A1 (fr) 2014-04-02 2015-04-02 Trousses pour la préparation de sites d'administration de médicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2015/024116 Ceased WO2015153899A1 (fr) 2014-04-02 2015-04-02 Trousses pour la préparation de sites d'administration de médicaments

Country Status (1)

Country Link
WO (2) WO2015153900A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017176910A1 (fr) * 2016-04-05 2017-10-12 H.N.S. International, Inc. Combinaison d'injecteur hypodermique sans aiguille et de feuille de couverture et procédés associés
KR101862679B1 (ko) * 2018-05-03 2018-05-31 박영오 켈로이드 치료용 주사키트
US20210196738A1 (en) * 2017-12-21 2021-07-01 Prebona Ab Pharmaceutical composition comprising a colloidal dispersion and a therapeutic agent and methods and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058605B2 (en) * 2018-03-08 2021-07-13 Flex Ltd. Sterilization fluid path with barrier removal
JP7210921B2 (ja) * 2018-07-23 2023-01-24 株式会社ダイセル 無針注射器
US12109318B1 (en) * 2021-06-11 2024-10-08 MJS Solutions, LLC Topical drug delivery devices and methods of use
WO2023072877A1 (fr) * 2021-10-25 2023-05-04 Ellennbe Gmbh Composition pharmaceutique et kit comprenant une substance immuno-modulatrice pour traiter des maladies
WO2024231720A1 (fr) * 2023-05-09 2024-11-14 Mahdi Mohammad Applicateur réutilisable comprenant un couvercle jetable

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600403A (en) * 1974-11-19 1986-07-15 Wolfgang Wagner Suction injector II
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
US6319224B1 (en) * 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6648850B2 (en) * 2001-06-08 2003-11-18 Bioject, Inc. Durable needle-less jet injector apparatus and method
WO2004101025A2 (fr) * 2003-05-09 2004-11-25 Intravacc, Inc. Injecteur hypodermique sans aiguille et ampoule pour injection intradermique, sous-cutanee et intramusculaire
US20080027384A1 (en) * 2003-06-04 2008-01-31 Wang Ping M Drilling microneedle device
US20110040280A1 (en) * 2008-03-28 2011-02-17 Terumo Kabushiki Kaisha Injector

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3605742A (en) * 1970-02-03 1971-09-20 Eugene E Tibbs Painless injection device
US6190367B1 (en) * 1999-09-22 2001-02-20 Becton, Dickinson And Company Medical site prep device
US20060287629A1 (en) * 2002-11-01 2006-12-21 Novo Nordisk A/S Jet injector with a bi-stable spring
US20070073267A1 (en) * 2005-09-27 2007-03-29 Mile Creek Capital, Llc Low-loss multi-lumen injection apparatus
MX2009010000A (es) * 2007-03-19 2010-03-17 Insuline Medical Ltd Dispositivo para el suministro de farmaco.
AU2010203354A1 (en) * 2009-01-12 2011-09-01 Aktivpak, Inc. Packaged products, inserts and compartments for aseptic mixing of substances, along with methods for use therewith
GB201109620D0 (en) * 2011-06-09 2011-07-20 Ardehali Massoud H Injection apparatus

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600403A (en) * 1974-11-19 1986-07-15 Wolfgang Wagner Suction injector II
US6319224B1 (en) * 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
US6648850B2 (en) * 2001-06-08 2003-11-18 Bioject, Inc. Durable needle-less jet injector apparatus and method
WO2004101025A2 (fr) * 2003-05-09 2004-11-25 Intravacc, Inc. Injecteur hypodermique sans aiguille et ampoule pour injection intradermique, sous-cutanee et intramusculaire
US20080027384A1 (en) * 2003-06-04 2008-01-31 Wang Ping M Drilling microneedle device
US20110040280A1 (en) * 2008-03-28 2011-02-17 Terumo Kabushiki Kaisha Injector

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017176910A1 (fr) * 2016-04-05 2017-10-12 H.N.S. International, Inc. Combinaison d'injecteur hypodermique sans aiguille et de feuille de couverture et procédés associés
US20210196738A1 (en) * 2017-12-21 2021-07-01 Prebona Ab Pharmaceutical composition comprising a colloidal dispersion and a therapeutic agent and methods and uses thereof
KR101862679B1 (ko) * 2018-05-03 2018-05-31 박영오 켈로이드 치료용 주사키트

Also Published As

Publication number Publication date
WO2015153899A1 (fr) 2015-10-08

Similar Documents

Publication Publication Date Title
WO2015153900A1 (fr) Kits de préparation de sites d'administration d'un médicament
RU2508135C2 (ru) Матрица полых микроигл
US20250325751A1 (en) Beneficial agent dispenser
JP5848132B2 (ja) 薬物容器および送達メカニズム
CN104870049B (zh) 粘合剂组件和包括该粘合剂组件的微针注入设备
RU2587011C2 (ru) Усовершенствованные безыгольные инъекторы
JP6411888B2 (ja) 中空マイクロニードルアレイのための送達システム
CN113301933A (zh) 鼻腔药品输送装置
US20250009972A1 (en) Systems, devices, and methods for fluidic throttle control of the delivery of therapies in needle-based delivery systems
JP2015520625A (ja) 薬物送達カプセルのためのピストン施栓
KR102007125B1 (ko) 다수의 소형 주사기 또는 주사부를 갖는 주사용 패드
JPH01198561A (ja) 液体注入装置
EP3193986A2 (fr) Procédé et appareil d'application d'un anesthésique et bactéricide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15773990

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase
122 Ep: pct application non-entry in european phase

Ref document number: 15773990

Country of ref document: EP

Kind code of ref document: A1